|
[1]
|
WHO (2021) Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019[Z/OL].
https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death, 2021-02-20.
|
|
[2]
|
王宇, 宋淑芳, 刘凤. 我国宫颈癌流行病学特征和发病高危因素的研究进展[J]. 中国妇幼保健, 2019, 34(5): 1206-1208.
|
|
[3]
|
Arora, E., Masab, M., Mittar, P., et al. (2018) Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer. Cureus, 10, e2521. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Linhares, A.D., Leitner, J., Grabmeier-Pfistershammer, K., et al. (2018) Not Alloimmune Checkpoints Are Created Equal. Frontiers in Immunology, 9, 1909. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Beatty, G.L. and Gladney, W.L. (2015) Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. Clinical Cancer Research, 21, 687-692. [Google Scholar] [CrossRef]
|
|
[7]
|
Zou, W. (2005) Immunosuppressive Networks in the Tumour Environment and Their Therapeutic Relevance. Nature Reviews Cancer, 5, 263-274. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Grupp, S.A., Kalos, M., Barrett, D., et al. (2013) Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. The New England Journal of Medicine, 368, 1509-1518. [Google Scholar] [CrossRef]
|
|
[10]
|
Son, J.Y., Park, S.Y., Kim, S.J., et al. (2014) EW-7197, a Novel ALK-5 Kinase Inhibitor, Potently Inhibits Breast to Lung Metastasis. Molecular Cancer Therapeutics, 13, 1704-1716. [Google Scholar] [CrossRef]
|
|
[11]
|
Couzin-Frankel, J. (2013) Breakthrough of the Year 2013. Cancer Immunotherapy. Science, 342, 1432-1433. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Heymach, J., Krilov, L., Alberg, A., et al. (2018) Clinical Cancer Advances 2018: Annual Report on Progress against Cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology, 36, 1020-1044. [Google Scholar] [CrossRef]
|
|
[13]
|
Sanmamed, M.F. and Chen, L. (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell, 175, 313-326. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Creelan, B.C. (2014) Update on Immune Checkpoint Inhibitors in Lung Cancer. Cancer Control, 21, 80-89. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three ES of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Vesely, M.D., Kershaw, M.H., Schreiber, R.D., et al. (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 29, 235-271. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Gong, J., Chehrazi-Raffle, A., Reddi, S., et al. (2018) Development of PD-1 and PD-L1 Inhibitors as a Form of Cancer Immunotherapy: A Comprehensive Review of Registration Trials and Future Considerations. Journal for Immuno Therapy of Cancer, 6, 8. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Barquin-Garcia, A., Molina-Cerrillo, J., Garrido, P., et al. (2019) New Oncologic Emergencies: What Is There to Know about Inmunotherapy and Its Potential Side Effects? European Journal of Internal Medicine, 66, 1-8.
|
|
[20]
|
Fajardo, C.A., Guedan, S., Rojas, L.A., et al. (2017) Oncolytic Adenoviral Delivery of an EGFR-Targeting T Cell Engager Improves Antitumor Efficacy. Cancer Research, 77, 2052-2063. [Google Scholar] [CrossRef]
|
|
[21]
|
Monney, L., Sabatos, C.A., Gaglia, J.L., et al. (2002) Th1-Specific Cell Surface Protein Tim-3 Regulates Macrophage Activation and Severity of an Autoimmune Disease. Nature, 415, 536-541. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Parra, E.R., Villalobos, P., Zhang, J., et al. (2018) Immunohistochemical and Image Analysis-Based Study Demonstrate That Several Immune Checkpoints Are Co-Expressed in Non-Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 13, 779-791. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wu, J., Lin, G., Zhu, Y., et al. (2017) Low TIM3 Expression Indicates Poor Prognosis of Metastatic Prostate Cancer and Acts as an Independent Predictor of Castration Resistant Status. Scientific Reports, 7, Article No. 8869. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Zhou, G., Sprengers, D., Boor, P.P.C., et al. (2017) Antibodies against Immune Checkpoint Molecules Restore Functions of Tumor Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology, 153, 1107. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Karabon, L., Partyka, A., Jasek, M., et al. (2016) Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia. Archivum Immunologiae et Therapiae Experimentalis, 64, 137-145. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Mcintire, J.J., Umetsu, S.E., Akbari, O., et al. (2001) Identification of Tapr (an Airway Hyperreactivity Regulatory Locus) and the Linked Tim Gene Family. Nature Immunology, 2, 1109-1116. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
陶景莲, 李丽娟, 邵宗鸿. TIM3在肿瘤微环境中作用的研究进展[J]. 中国免疫学杂志, 2016, 32(7): 1070-1073. [Google Scholar] [CrossRef]
|
|
[28]
|
Friedlaender, A., Addeo, A. and Banna, G. (2019) New Emerging Targets in Cancer Immunotherapy: The Role of TIM3. ESMO Open, 4, e000497. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Jacob, C., et al. (2020) Looking Past PD-L1: Expression of Immune Checkpoint TIM-3 and Its Ligand Galectin-9 in Cervical and Vulvar Squamous Neoplasia. Modern Pathology, 33, 1182-1192. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Das, M., Zhu, C. and Kuchroo, V.K. (2017) Tim-3 and Its Role in Regulating Anti-Tumor Immunity. Immunological Reviews, 276, 97-111. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Boles, K.S., Vermi, W., Facchetti, F., et al. (2009) A Novel Molecular Interaction for the Adhesion of Follicular CD4 T Cells to Follicular DC. European Journal of Immunology, 39, 695-703. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Lozano, E., Dominguez-Villar, M., Kuchroo, V., et al. (2012) The TIGIT/CD226 Axis Regulates Human T Cell Function. The Journal of Immunology, 188, 3869-3875. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Johnston, R.J., Comps-Agrar, L., Hackney, J., et al. (2014) The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8(+) T Cell Effector Function. Cancer Cell, 26, 923-937. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Stanietsky, N., Simic, H., Arapovic, J., et al. (2009) The Interaction of TIGIT with PVR and PVRL2 Inhibits Human NK Cell Cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 106, 17858-17863. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Minu, K., Srivastava, R.Y., Erin, M., et al. (2017) Abstract 2612: Anti-TIGIT Induces T Cell Mediated Anti-Tumor Immune Response and Combines with Immune Checkpoint Inhibitors to Enhance Strong and Long Term Anti-Tumor Immunity. Cancer Research, 77, 2612-2612. [Google Scholar] [CrossRef]
|
|
[36]
|
Park, A.I., Srivastava, M., Mayes, E., et al. (2017) Abstract 2003: Antibody against TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains) Induces Anti-Tumor Immune Response and Generates Long-Term Immune Memory. Cancer Research, 77, 2003. [Google Scholar] [CrossRef]
|
|
[37]
|
Blessin, N.C., Simon, R., Kluth, M., et al. (2019) Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer. Annals of Surgical Oncology, 2019, Article ID: 5160565.
|
|
[38]
|
Triebel, F., Jitsukawa, S., Baixeras, E., et al. (1990) LAG-3, a Novel Lymphocyte Activation Gene Closely Related to CD4. Journal of Experimental Medicine, 171, 1393-1405. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Anderson, A.C., Joller, N. and Kuchroo, V.K. (2016) Lag-3, TIM-3, and TIGIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 44, 989-1004. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Joller, N. and Kuchroo, V.K. (2017) Tim-3, Lag-3, and TIGIT. Current Topics in Microbiology and Immunology, 410, 127-156. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Dijkstra, J.M., Somamoto, T., Moore, L., et al. (2006) Identification and Characterization of a Second CD4-Like Gene in Teleost Fish. Molecular Immunology, 43, 410-419. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Di Carlo, E., Cappello, P., Sorrentino, C., et al. (2005) Immunological Mechanisms Elicited at the Tumour Site by Lymphocyte Activation Gene-3 (LAG-3) versus IL-12: Sharing a Common Th1 Anti-Tumour Immune Pathway. The Journal of Pathology, 205, 82-91. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Gros, A., Robbins, P.F., Yao, X., et al. (2014) PD-1 Identifies the Patient-Specific CD8(+) Tumor-Reactive Repertoire Infiltrating Human Tumors. Journal of Clinical Investigation, 124, 2246-2259. [Google Scholar] [CrossRef]
|
|
[44]
|
He, Y., Rivard, C.J., Rozeboom, L., et al. (2016) Lymphocyte-Activation Gene-3, an Important Immune Checkpoint in Cancer. Cancer Science, 107, 1193-1197. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Burugu, S., Gao, D., Leung, S., et al. (2017) LAG-3+ Tumor Infiltrating Lymphocytesin Breast Cancer: Clinical Correlates and Association with PD-1/PD-L1+ Tumors. Annals of Oncology, 28, 2977-2984. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Feng, Y., Zhong, M., Liu, Y., et al. (2018) Expression of TIM-3 and LAG-3 in Extranodal NK/T Cell Lymphoma, Nasal Type. Histology and Histopathology, 33, 307-315.
|
|
[47]
|
Zhang, M., et al. (2018) VISTA Expression Associated with CD8 Confers a Favorable Immune Microenvironment and Better Overall Survival in Hepatocellular Carcinoma. BMC Cancer, 18, Article No. 511. [Google Scholar] [CrossRef] [PubMed]
|